ENSTILAR

Peak

calcipotriene and betamethasone dipropionate

NDATOPICALAEROSOL, FOAM
Approved
Oct 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2

Mechanism of Action

D3 analog and betamethasone dipropionate as a synthetic corticosteroid. However, while their pharmacologic and clinical effects are known, the exact mechanisms of their actions in the treatment of plaque psoriasis are unknown.

Indications (1)

Clinical Trials (2)

NCT04372277Phase 4Recruiting

Taltz in Combination With Enstilar for Psoriasis

Started Apr 2020
25 enrolled
Psoriasis
NCT03587194Phase 4Completed

Evaluation of Add on Enstilar in Patients Using Otezla for Psoriasis

Started Jul 2018
50 enrolled
Psoriasis

Loss of Exclusivity

LOE Date
Dec 10, 2031
70 months away
Patent Expiry
Dec 10, 2031

Patent Records (5)

Patent #ExpiryTypeUse Code
9566286
Jun 10, 2031
Product
9119781
Jun 10, 2031
Product
U-2627
10130640
Jun 10, 2031
Product
10617698
Jun 10, 2031
Product
10660908
Jun 10, 2031
Product
U-2627